Thanks,
@Atlas for uploading this great news. Below is the English translation by Google. I have made a few editing though. There may be some mistakes in editing but I tried not to interfere with the theme of this news.
-@bluesky-
Conditional approval of conditional ‘Bangovax’ ticker human trial
The approval was given by the Department of Drug Administration on Wednesday (June 18) at noon.
Rashed Limon
The Bangladesh Medical Research Council (BMRC) has given conditional approval to the human trial of the 'Bangovax' Vaccine of the domestic Globe Biotech conditionally. The approval was given by the BMRC on Wednesday (June 18) at noon.
BMRC Director Prof. Ruhul Amin said that the permission was given on conditions. If you can fix the mistake, we will allow it. Approval will be given if the conditions are met.
It is learned that with the permission of BMRC, a trial of this Vaccine will be conducted on hundreds of people very soon. Some private hospitals have been set up for this.
Earlier, it was published in the American Medical Journal that the corona vaccine Bangovax of Globe Biotech is effective in animals. The company was then awaiting BMRC approval for a human-body trial. The institution was given conditional approval.
According to the US medical journal Vaccine, Bangovax is the
world's first effective single-dose vaccine made from mRNA technology that has successfully protected human cells and animals against the SARS-COV-2 virus. After the publication of this research paper, the vaccine of the Globe Biotech came up to the fore again.
Kakon Nag, CEO of Globe Biotech, said: "Rumors were spreading in the market about our vaccine. However, the fact that our research article was published in a US medical journal proved that our claim to create a vaccine is genuine.
Pre-clinical studies have shown that the vaccine is tolerable and safe in human cells and animals. Globe Biotech claims that this vaccine will protect the human body for at least 6 months.
He said the vaccine is tolerant and safe in human cells and animals. For now, we can say that it has worked 100 percent in the animal body. We can supply one crore doses of vaccine every month. If any other company wants to work with this vaccine, we can work with them. The vaccine does not require a specifically dedicated facility in accordance with World Health Organization guidelines.
As part of a clinical trial, the drug administration delegated permission to produce the vaccine on December 26 last year. A letter was sent to BMRC on February 18 this year seeking that approval.
